Background: The establishment of definitive treatment against COVID-19 infection has not yet reached the finish line. Thrombosis and hypercoagulation in advanced stages are other vital issues. Further study on how to use anticoagulants is still being analyzed in order to embody the best prognosis.

Aims: Evaluating the use of anticoagulants in moderate to critically ill COVID-19 patients.

Methods: We conducted a retrospective cohort study involving 218 patients with moderate to critically ill conditions, in which 42 of them received anticoagulants. All cause-mortality, length of stay, and the average day of death were investigated.

Results: Of the 42 patients who received anticoagulants, 18 cases of moderate COVID were given anticoagulants and there was no death with a length of stay of 16.1 days vs 12.58 days without anticoagulants (p = 0.054). Five severe cases of COVID were given anticoagulants and no deaths occurred in severe cases with a length of treatment of 13.2 days vs 16.57 days without anticoagulants (p = 0.315). In cases of critical illness, death occurred in 9 cases of 19 who were given anticoagulants compared to 9 deaths that occurred in 33 cases without anticoagulants with a comparison of length of treatment of 15.8 vs 15 days (without anticoagulants) (p = 0.72). The mean days of death on anticoagulant administration in critically ill cases were 20.7 days and 25.3 days in patients without anticoagulants (p = 0.274).

Conclusions: The administration of anticoagulants to moderate to critically-ill COVID-19 patients did not ameliorate the length of treatment and all-cause mortality.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/anti-coagulant-drugs-among-moderate-severe-and-critically-ill-covid-19-patients-in-the-second-referral-hospital-in-surabaya/